Development of a lethal adult mouse model of Coxsackievirus B1 infection for antiviral research Authors: Changjian Fang, Kang Yu, Jia Xue, Wenkun Fu, Nanyi Liu, Chuanlai Yang, Wensong Su, Shiying Xu, Jiaoling Zhang, Aping Lin, Dequan Pan, Ningshao Xia, Linghui Zhan, Wei Wang, Tong Cheng Published: 2026 ABSTRACT SummaryCoxsackievirus B1 (CVB1), a clinically significant human enterovirus, causes a wide spectrum of diseases ranging from mild illness to severe, life-threatening conditions in susceptible individuals. However, investigations into CVB1 infection pathogenesis, as well as the development and evaluation of antiviral strategies, have long been constrained by the lack of immunocompetent animal models that recapitulate human CVB1 infections. In this study, we established a lethal CVB1 infection model in immunocompetent adult BALB/c mice. Using a reverse genetics approach, we generated the CVB1-XM0108 virus from a clinical isolate and infected adult BALB/c mice. Our results demonstrated that this virus exhibited a strong tropism for the pancreas, liver, and skeletal muscles, leading to extensive inflammation in these organs. Passive immunization with anti-CVB1 serum dose-dependently reduced viral replication, tissue damage, weight loss, and mortality. This pathologically relevant mouse model provides a valuable platform for advancing CVB1 therapeutic and vaccine development. Introduction Coxsackievirus B1 (CVB1), a member of the genus Enterovirus in the family Picornaviridae, is a ubiquitous human pathogen posing significant public health concerns worldwide. Most CVB1 infections present with flu-like symptoms, and the virus is also one of the major pathogens of hand-foot-mouth disease (HFMD).1,2 Reports have shown that CVB1 infection is associated with severe systemic infectious diseases in neonates, including myocarditis,3 aseptic meningitis,4,5 hepatitis,6 and even death.7 In addition, several studies have suggested that CVB1 acts as an environmental trigger for type 1 diabetes mellitus (T1D).8,9,10,11 The absence of effective antiviral therapies or prophylactic vaccines against CVB1 poses a substantial global public health burden. Consequently, this unmet medical need underscores the urgency to elucidate CVB1 pathogenesis and develop targeted antiviral strategies. Vaccines represent critical tools for combating viral infections, and their development relies on appropriate animal infection models for evaluation. Current animal models for CVBs infection primarily include non-human primates, mice, and hamsters.12 Given their ability to recapitulate human clinical manifestations of enterovirus infection combined with ethical, practical, and cost advantages, BALB/c mice serve as a preferred animal model. However, current CVB1 mouse infection models primarily utilize neonatal mice.13,14,15,16 The immature immune system of neonatal mice renders them highly susceptible to viral pathogens. Furthermore, CVB1-induced human diseases, particularly chronic conditions, are frequently associated with host immune dysregulation.17,18,19,20 Consequently, adult BALB/c mice with a fully developed immune system offer a more physiologically relevant model for studying CVB pathogenicity in the context of immune system responses. Nevertheless, a detailed characterization of CVB1 pathology in adult mice remains unreported. Here, a full-length infectious cDNA clone of clinical isolate CVB1-XM0108 was constructed and characterized in vitro and in vivo. The rescued virus recapitulated parental strain phenotypes in vitro. Following intravenous inoculation of 7-week-old BALB/c mice, CVB1-XM0108 infection induced weight loss, paralysis, and mortality. Histopathological analysis confirmed acute pancreatitis, hepatitis, and myositis, with high viral loads detected in these target tissues. An optimal infectious dose was established, yielding a lethal adult mouse model exhibiting multi-organ involvement. Furthermore, passive immunization validated this model’s utility for vaccine evaluation. This work provides a valuable virological tool for characterizing CVB1 strains and serves as an evaluation platform for developing antiviral drugs and vaccines. Results In vitro characterization of CVB1-XM0108 rescued from an infectious cDNA clone The CVB1-XM0108 strain was isolated from the cerebrospinal fluid of a patient with meningitis. Phylogenetic analysis of all available CVB1 genomes positioned CVB1-XM0108 within a cluster of epidemic strains from Shandong and Yunnan provinces, China (e.g., CVB1SD2011CHN, CVB1-MSH/KM9/2009), while demonstrating genetic divergence from prototype strain Conn-5 and US isolates such as Chi07 (Figure S1). To generate an infectious clone for CVB1-XM0108, its full-genome sequence was cloned into the pSVA vector containing a T7 promoter, yielding the plasmid pSVA-CVB1-XM0108. Viral genomic RNA was transcribed in vitro from the linearized cDNA clone using T7 polymerase (Figure 1A), and the transcribed RNA was transfected into HeLa cells to rescue infectious virus. At 14 h post-transfection, HeLa cells displayed cytopathic effects (CPEs), including cell shrinkage, rounding, and lysis, which were indistinguishable from those induced by the parental strain at an MOI of 0.1 (Figure 1B). Transmission electron microscopy of viral particles isolated from culture supernatants revealed icosahedral, unenveloped virions with a diameter of ∼30 nm (Figure 1C), consistent with the morphological characteristics of enterovirus. These results suggest the successful rescue of infectious virus, and the virus derived from the infectious clone pSVA-CVB1-XM0108 was designated rCVB1-XM0108.Figure 1Rescue and characterization of rCVB1-XM0108 strain derived from the cDNA clone(A) The viral genomic RNA of CVB1-XM0108 generated by in vitro transcription of the infectious cDNA clone.(B) Characterization of cytopathic effects induced by CVB1-XM0108 and rCVB1-XM0108 in HeLa cells at 12 hpi.(C) Visualization of CVB1 viral particles using transmission electron microscopic analysis.(D) Dose-response cytotoxicity of CVB1-XM0108 and rCVB1-XM0108 in HeLa cells was assessed across a logarithmic MOI range (101 to 10−5). Viability measurements (n = 3 per point) from three independent experiments are expressed as percentages of untreated controls and presented as mean ± SEM.(E) Comparative one-step growth curves of CVB1-XM0108 and rCVB1-XM0108 (MOI = 0.1) in HeLa cells. Viral progeny production was monitored at indicated time points (n = 3 per time point) through three independent experiments, presented as means ± SEM.(F) Immunofluorescence staining for viral VP1 protein (green) and double-stranded RNA (red) in HeLa cells infected with CVB1 strains at an MOI of 1 for 14 h. The cell nuclei were stained blue using DAPI. Scale bars: 200 μm in (B), 50 nm in (C), and 10 μm in (F), respectively. Rescue and characterization of rCVB1-XM0108 strain derived from the cDNA clone (A) The viral genomic RNA of CVB1-XM0108 generated by in vitro transcription of the infectious cDNA clone. (B) Characterization of cytopathic effects induced by CVB1-XM0108 and rCVB1-XM0108 in HeLa cells at 12 hpi. (C) Visualization of CVB1 viral particles using transmission electron microscopic analysis. (D) Dose-response cytotoxicity of CVB1-XM0108 and rCVB1-XM0108 in HeLa cells was assessed across a logarithmic MOI range (101 to 10−5). Viability measurements (n = 3 per point) from three independent experiments are expressed as percentages of untreated controls and presented as mean ± SEM. (E) Comparative one-step growth curves of CVB1-XM0108 and rCVB1-XM0108 (MOI = 0.1) in HeLa cells. Viral progeny production was monitored at indicated time points (n = 3 per time point) through three independent experiments, presented as means ± SEM. (F) Immunofluorescence staining for viral VP1 protein (green) and double-stranded RNA (red) in HeLa cells infected with CVB1 strains at an MOI of 1 for 14 h. The cell nuclei were stained blue using DAPI. Scale bars: 200 μm in (B), 50 nm in (C), and 10 μm in (F), respectively. To assess infectivity, both the parental virus CVB1-XM0108 and the rescued virus rCVB1-XM0108 were inoculated into HeLa cells at 10-fold gradient MOIs (101 to 10−5). The two viruses induced comparable CPE (Figure 1D). One-step growth curve analysis at an MOI of 0.1 showed similar replication kinetics between the parental and the rescued viruses (Figure 1E). Immunofluorescence staining confirmed the expression of enteroviral VP1 protein and double-stranded RNA in infected cells (Figure 1F) validating active viral replication by both strains. Overall, the rCVB1-XM0108 strain faithfully recapitulates the virological properties of the parental CVB1-XM0108. For experimental consistency, rCVB1-XM0108 was selected over the parental clinical isolate to minimize potential contamination, ensure purity, and facilitate reproducible in vivo studies. Virulence characterization of rCVB1-XM0108 in BALB/c mice Inbred BALB/c mice are widely used for enterovirus infection modeling due to their ability to recapitulate clinical manifestations of human viral infections.12 To characterize the in vivo virulence of rCVB1-XM0108, 7-week-old adult BALB/c mice were intravenously challenged with 10-fold gradient dosages (1 × 105–1 × 108 50% tissue culture infectious dose [TCID50]/mouse, n = 6 per group). Body weight, clinical symptoms, and survival rates were monitored daily for 21 days (Figures 2A–2C).Figure 2Virulence characterization of rCVB1-XM0108 in BALB/c infection modelDose-dependent paralysis and mortality in 7-week-old BALB/c mice infected with serial doses of rCVB1-XM0108 (1 × 105–1 × 108 TCID50).(A) Body weight (mean ± SEM), (B) clinical scores (mean ± SEM), and (C) survival rates were monitored for 21 days post-infection (n = 6 per group). (D) Representative clinical manifestations including progressive emaciation and hunched posture in rCVB1-XM0108-infected mice compared with mock-infected control. Statistical significance between dose groups was annotated on the graphs. For statistical analysis, body weight (A) was analyzed using a mixed-effects model with the Šídák multiple-comparisons test, clinical scores (B) were analyzed using two-way ANOVA, and survival curves (C) were compared using the log rank (Mantel-Cox) test. ∗, p < 0.05; ∗∗∗∗, p < 0.0001. Experiments were independently repeated three times, and representative results are shown. Virulence characterization of rCVB1-XM0108 in BALB/c infection model Dose-dependent paralysis and mortality in 7-week-old BALB/c mice infected with serial doses of rCVB1-XM0108 (1 × 105–1 × 108 TCID50). (A) Body weight (mean ± SEM), (B) clinical scores (mean ± SEM), and (C) survival rates were monitored for 21 days post-infection (n = 6 per group). (D) Representative clinical manifestations including progressive emaciation and hunched posture in rCVB1-XM0108-infected mice compared with mock-infected control. Statistical significance between dose groups was annotated on the graphs. For statistical analysis, body weight (A) was analyzed using a mixed-effects model with the Šídák multiple-comparisons test, clinical scores (B) were analyzed using two-way ANOVA, and survival curves (C) were compared using the log rank (Mantel-Cox) test. ∗, p < 0.05; ∗∗∗∗, p < 0.0001. Experiments were independently repeated three times, and representative results are shown. At the highest dose of 1 × 108 TCID50/mouse, infected BALB/c mice exhibited rapid body weight loss (7.5–17.9%), accompanied by acute limb weakness, paralysis, and terminal moribundity, with 100% mortality by 5 days post-infection (dpi) (Figure 2D). Mice challenged with 1 × 107 TCID50/mouse developed progressive symptoms, leading to 100% mortality by 11 dpi. In contrast, the 1 × 106 TCID50/mouse group displayed significant limb weakness, hunched posture, and sustained weight loss but maintained an 83.3% survival rate over 21 days. Notably, the lowest dose (1 × 105 TCID50/mouse) induced transient clinical scores of 3 (3–7 dpi), followed by symptom resolution, weight recovery, and 100% survival. PBS-injected control mice remained asymptomatic throughout the observation period. Based on these survival data, the 50% lethal dose (LD50) of rCVB1-XM0108 in BALB/c mice was calculated using the Spearman-Kärber method to be 2.15 × 106 TCID50/mouse. These data indicate that a dose of 1 × 107 TCID50/mouse induced progressive lethal infection within 11 days, making it suitable for establishing a lethal infection mouse model in subsequent in vivo studies. rCVB1-XM0108 induces multiorgan damage with distinct serum biomarker profiles Following CVB1-XM0108 infection, most mice rapidly exhibited disease symptoms, including weight loss and paralysis. Anatomical examination of infected mice revealed significant edema and friability in the pancreases (Figure 3A). To characterize tissue tropism and pathological changes, BALB/c mice were intravenously inoculated with a dose of 1 × 107 TCID50 of rCVB1-XM0108, and histopathological analysis was performed on tissues (heart, liver, spleen, lung, kidney, brain, pancreas, and limb muscle) from moribund mice.Figure 3Pathological alterations and serum biochemistry in rCVB1-XM0108-infected BALB/c miceSeven-week-old BALB/c mice were intravenously injected with 1 × 107 TCID50/mouse of rCVB1-XM0108 or equal volume of PBS (mock). At 4 days post-infection (dpi), organs (heart, liver, spleen, lung, kidney, brain, pancreas, and limb muscle) were harvested from moribund mice for histopathological analysis. Concurrently, serum biochemical parameters were assessed over 7 dpi.(A) Pancreatic histology showing acute inflammatory lesions (solid black triangles).(B and C) Comparative H&E staining and VP1 immunohistochemistry (IHC) of PBS (B) and rCVB1-XM0108-infected (C) tissues. In mock pancreas (B), dashed line demarcated islet architecture. rCVB1-XM0108-infected pancreas (C) exhibited disrupted islet-acinar interfaces (open triangle) and VP1+ signals in exocrine pancreas (solid triangle). Scale bars: 50 μm.(D–F) Serum biochemistry (n = 5 per time point) revealed elevated α-amylase (α-AMY) (D), alanine aminotransferase (ALT) (E), and aspartate aminotransferase (AST) (F) levels during the acute infection period (1–7 dpi). Data are shown as individual values, with the horizontal line indicating the mean. Data were analyzed by the unpaired two-tailed Student t test in GraphPad Prism 10.0. n.s., not significant; ∗, p < 0.05; ∗∗, p < 0.01; ∗∗∗, p < 0.001; ∗∗∗∗, p < 0.0001. Experiments were independently repeated three times, and representative results are shown. Pathological alterations and serum biochemistry in rCVB1-XM0108-infected BALB/c mice Seven-week-old BALB/c mice were intravenously injected with 1 × 107 TCID50/mouse of rCVB1-XM0108 or equal volume of PBS (mock). At 4 days post-infection (dpi), organs (heart, liver, spleen, lung, kidney, brain, pancreas, and limb muscle) were harvested from moribund mice for histopathological analysis. Concurrently, serum biochemical parameters were assessed over 7 dpi. (A) Pancreatic histology showing acute inflammatory lesions (solid black triangles). (B and C) Comparative H&E staining and VP1 immunohistochemistry (IHC) of PBS (B) and rCVB1-XM0108-infected (C) tissues. In mock pancreas (B), dashed line demarcated islet architecture. rCVB1-XM0108-infected pancreas (C) exhibited disrupted islet-acinar interfaces (open triangle) and VP1+ signals in exocrine pancreas (solid triangle). Scale bars: 50 μm. (D–F) Serum biochemistry (n = 5 per time point) revealed elevated α-amylase (α-AMY) (D), alanine aminotransferase (ALT) (E), and aspartate aminotransferase (AST) (F) levels during the acute infection period (1–7 dpi). Data are shown as individual values, with the horizontal line indicating the mean. Data were analyzed by the unpaired two-tailed Student t test in GraphPad Prism 10.0. n.s., not significant; ∗, p < 0.05; ∗∗, p < 0.01; ∗∗∗, p < 0.001; ∗∗∗∗, p < 0.0001. Experiments were independently repeated three times, and representative results are shown. Figures 3B and 3C show comparative H&E staining and VP1 immunohistochemistry (IHC) of visceral organs from PBS controls and infected mice, respectively. Histopathological analysis of the pancreas revealed extensive mononuclear cell infiltration (predominantly in exocrine regions), architectural disorganization, acinar cell necrosis, hydropic degeneration, and disruption of exocrine structures, which were consistent with gross anatomical observations. VP1-IHC confirmed intense viral protein deposition throughout pancreatic tissues (solid triangle, Figure 3C), particularly in exocrine compartments. Notably, viral disruption of the islet-acinar interface (open triangle, Figure 3C) facilitated inflammatory infiltration, potentially priming β-cell autoimmune responses associated with T1D pathogenesis. Hepatic pathology showed pronounced inflammatory infiltrates, hepatocellular vacuolization, and abundant VP1 expression, corresponding to the yellowish discoloration observed in infected livers. Skeletal muscle sections exhibited myofiber degeneration with positive VP1 staining, explaining hindlimb paralysis in late-stage infection. PBS control mice exhibited no pathological changes, with undetectable VP1 in all organs. Serum samples collected daily (0–7 dpi) were analyzed for biochemical markers. As shown in Figure 3D, serum α-AMY levels surged on day 1, peaked at ∼50,000 U/L (20-fold higher than PBS controls) on day 3, and declined to baseline by day 5. This pattern confirmed acute pancreatic injury, consistent with IHC evidence of viral replication in pancreatic tissues. Concurrently, liver function markers alanine aminotransferase and aspartate aminotransferase (Figures 3E and 3F) exhibited similar kinetics, peaking on days 4 and 3, respectively, before decreasing. Together, these histopathological and biochemical findings characterize acute CVB1-induced pancreatic and liver injury in mice, providing evidence for multiorgan tropism during CVB1-XM0108 infection. Cellular tropism of rCVB1-XM0108 in the murine pancreas Histopathological evaluation revealed extensive VP1 protein expression in pancreas of rCVB1-XM0108-infected mice. To characterize cellular tropism, multiplex immunofluorescence co-staining for insulin (β-cells), glucagon (α-cells), and viral protein VP1 was performed. Figures 4A and 4B show representative pancreatic sections from PBS controls and infected mice, respectively. Viral replication was predominantly detected in exocrine compartments, evidenced by widespread VP1+ signals (green). Notably, VP1 fluorescence did not co-localize with insulin (red) or glucagon (yellow), confirming that the virus was excluded from islet endocrine cells despite structural disruption of islet-acinar interfaces. In contrast, PBS controls exhibited intact islet architecture without detectable VP1 signals.Figure 4Tissue tropism of rCVB1-XM0108 in murine pancreasPancreatic tissues were harvested from 7-week-old BALB/c mice at 4 days post-infection with 1 × 107 TCID50/mouse of rCVB1-XM0108 or PBS (mock). Multiplex immunofluorescence analysis was performed on serial sections co-stained for insulin (red), glucagon (yellow), VP1 protein (green), and DAPI (blue).(A) Mock-infected control showing intact islet-acinar architecture.(B) rCVB1-XM0108-infected pancreas demonstrating viral tropism for exocrine regions. Scale bars: 100 μm. Representative images from three independent experiments are shown. Tissue tropism of rCVB1-XM0108 in murine pancreas Pancreatic tissues were harvested from 7-week-old BALB/c mice at 4 days post-infection with 1 × 107 TCID50/mouse of rCVB1-XM0108 or PBS (mock). Multiplex immunofluorescence analysis was performed on serial sections co-stained for insulin (red), glucagon (yellow), VP1 protein (green), and DAPI (blue). (A) Mock-infected control showing intact islet-acinar architecture. (B) rCVB1-XM0108-infected pancreas demonstrating viral tropism for exocrine regions. Scale bars: 100 μm. Representative images from three independent experiments are shown. Tissue viral load in rCVB1-XM0108-infected mice To investigate the in vivo replication dynamics of rCVB1-XM0108, BALB/c mice were intravenously inoculated with 1 × 107 TCID50 of rCVB1-XM0108. Serum and various organ samples, including the heart, liver, spleen, lung, kidney, brain, pancreas, and hindlimb muscle, were collected over the first six days post-infection for RT-qPCR analysis (n = 3 per time point). As shown in Figure 5, viral loads displayed a biphasic pattern: a rapid increase within 3–4 days post-inoculation, followed by gradual clearance. This indicated efficient viral replication across multiple tissues, with progressive elimination over time.Figure 5Tissue viral load in rCVB1-XM0108-infected miceSeven-week-old BALB/c mice were intravenously inoculated with rCVB1-XM0108 at a dose of 1 × 107 TCID50/mouse. Serum and tissue samples (including heart, liver, spleen, lung, kidney, brain, pancreas, and limb muscle) were collected daily from 1 to 6 days post-infection (dpi). Subsequently, viral RNA copies in these tissues were quantified by RT-qPCR. As shown in the figure, viral loads across different tissues are presented as mean log10 copies/mL or/mg tissue ± SEM (n = 3 per time point). For reproducibility, the experiment was independently repeated three times, with representative results displayed. Tissue viral load in rCVB1-XM0108-infected mice Seven-week-old BALB/c mice were intravenously inoculated with rCVB1-XM0108 at a dose of 1 × 107 TCID50/mouse. Serum and tissue samples (including heart, liver, spleen, lung, kidney, brain, pancreas, and limb muscle) were collected daily from 1 to 6 days post-infection (dpi). Subsequently, viral RNA copies in these tissues were quantified by RT-qPCR. As shown in the figure, viral loads across different tissues are presented as mean log10 copies/mL or/mg tissue ± SEM (n = 3 per time point). For reproducibility, the experiment was independently repeated three times, with representative results displayed. In serum, viral RNA copies peaked at 7.04×107 copies/mL on day 3 (3 dpi), then decreased to 1.75×105 copies/mL by day 6, confirming systemic viremia and viral dissemination to peripheral organs. The pancreas harbored the highest viral load, reaching 2.74×108 copies/mg at 3 dpi, with only a modest decline from days 4–6, suggesting persistent replication in pancreatic tissue beyond the acute phase. Hepatic viral loads peaked at 2.56×106 copies/mg tissue on day 3, remained elevated on day 4 (7.24×104 copies/mg), and subsequently dropped sharply on days 5–6 (2.64×102 copies/mg). Similarly, limb muscle viral loads peaked at 1.40×107 copies/mg on day 3 and remained high through day 6. These kinetics correlated with histopathological and IHC findings, indicating that rCVB1-XM0108 preferentially replicates in the pancreas, liver, and limb muscles, driving pancreatic/liver injury and hindlimb paralysis that contribute to mortality. Inflammatory responses to rCVB1-XM0108 infection in BALB/c mice To assess inflammatory responses following rCVB1-XM0108 infection, 7-week-old BALB/c mice were intravenously inoculated with 1 × 107 TCID50/mouse. Serum was collected at 4 dpi and analyzed using the Mouse Cytokine Array Panel A (R&D Systems) (Figure 6A). Subsequent profiling revealed significant upregulation of seven inflammatory mediators in infected mice compared with PBS controls (Figures 6B and 6C). The acute-phase chemokines CXCL1 (4.9-fold increase) and CXCL10 (6.9-fold increase) were associated with neutrophil recruitment and T cell chemotaxis, respectively. Concurrent elevations in chemokines CCL2 (10.2-fold increase) and CCL12 (3.4-fold increase) suggested enhanced myeloid mobilization. The lymphoid-organizing chemokine CXCL13 (7.1-fold increase) and hematopoietic factor G-CSF (4.1-fold increase) indicated ectopic lymphoid formation and granulopoiesis, while a 9.6-fold rise in TIMP-1 reflected tissue remodeling activity. Unexpectedly, conventional pro-inflammatory cytokines (IL-6, IL-10, IFN-γ, TNF-α) were undetectable by the membrane-based array. Longitudinal ELISA analysis of serum (1–7 dpi) revealed biphasic expression kinetics for IL-6, IL-10, IFN-γ, and TNF-α (Figures 6D–6G). These cytokines exhibited acute-phase peaks at 3 dpi, followed by progressive decline, mirroring viral load dynamics in target organs.Figure 6Evaluation of inflammatory responses in vivoSeven-week-old BALB/c mice were intravenously inoculated with 1 × 107 TCID50/mouse of rCVB1-XM0108. Serum was collected at 4 days post-infection (dpi) and analyzed using the Mouse Cytokine Array Panel A (R&D Systems).(A) Displaying a 40-cytokine detection matrix.(B) Representative cytokine expression profiles in rCVB1-XM0108-infected serum compared with PBS controls, with significantly altered cytokines/chemokines boxed in black.(C) Quantified serum cytokine levels (mean ± SEM, n = 3 per group).(D–G) IL-6, IL-10, IFN-γ, and TNF-α levels were measured by ELISA from 1–7 dpi (n = 5 per time point). Data are shown as individual values, with the horizontal line indicating the mean. Data were analyzed by the unpaired two-tailed Student t test in GraphPad Prism 10.0. n.s., not significant; ∗, p < 0.05; ∗∗, p < 0.01; ∗∗∗, p < 0.001; ∗∗∗∗, p < 0.0001. Experiments were independently repeated three times, and representative results are shown. Evaluation of inflammatory responses in vivo Seven-week-old BALB/c mice were intravenously inoculated with 1 × 107 TCID50/mouse of rCVB1-XM0108. Serum was collected at 4 days post-infection (dpi) and analyzed using the Mouse Cytokine Array Panel A (R&D Systems). (A) Displaying a 40-cytokine detection matrix. (B) Representative cytokine expression profiles in rCVB1-XM0108-infected serum compared with PBS controls, with significantly altered cytokines/chemokines boxed in black. (C) Quantified serum cytokine levels (mean ± SEM, n = 3 per group). (D–G) IL-6, IL-10, IFN-γ, and TNF-α levels were measured by ELISA from 1–7 dpi (n = 5 per time point). Data are shown as individual values, with the horizontal line indicating the mean. Data were analyzed by the unpaired two-tailed Student t test in GraphPad Prism 10.0. n.s., not significant; ∗, p < 0.05; ∗∗, p < 0.01; ∗∗∗, p < 0.001; ∗∗∗∗, p < 0.0001. Experiments were independently repeated three times, and representative results are shown. These findings indicate that rCVB1-XM0108 triggers acute inflammatory responses (3–4 dpi) coinciding with severe pancreatic and hepatic pathology, leading to lethality at high inoculum doses (1 × 107 TCID50). Inflammation resolved to baseline levels by 6 dpi, paralleling viral clearance. Protective efficacy of anti-CVB1 sera against rCVB1-XM0108 infection in vivo To establish a model for evaluating anti-CVB1 interventions, 7-week-old BALB/c mice (n = 6 per group) were intravenously inoculated with 1 × 107 TCID50 of rCVB1-XM0108. At 2 h post-infection (hpi), anti-CVB1 sera (geometric mean neutralizing titer: 1:1024) were administered via intraperitoneal injection at 10-fold-diluted concentrations (1:10 to 1:10,000), with PBS as the control. As shown in Figures 7A–7C, mice treated with 1:10-diluted anti-CVB1 sera exhibited mild lethargy but recovered rapidly, like uninfected mice. At a 1:100 dilution, mice experienced transient weight loss but regained baseline weight within 1 week. Notably, 1:1,000-diluted antisera provided only partial protection, leading to 33.3% mortality. Conversely, the 1:10,000 dilution failed to protect mice, which developed severe symptoms such as limb paralysis and moribundity by 3–4 dpi and died within one week, with phenotypes identical to those of PBS controls.Figure 7Protection efficacy of anti-CVB1 sera in BALB/c infection model(A–C) Seven-week-old BALB/c mice (n = 6 per group) were intravenously inoculated with 1 × 107 TCID50/mouse of rCVB1-XM0108. At 2 h post-infection, 200 μL of serially diluted anti-CVB1 sera or PBS were intraperitoneally administered. Mice were monitored for 21 days to assess (A) body weight (mean ± SEM), (B) clinical scores (mean ± SEM), and (C) survival rates. Statistical significance between dose groups was annotated on the graphs. Clinical scores (B) were analyzed using a mixed-effects model with the Šídák multiple-comparisons test. Survival curves (C) were compared using the log rank (Mantel-Cox) test. ∗∗, p < 0.01; ∗∗∗∗, p < 0.0001. Experiments were independently repeated three times, and representative results are shown. Protection efficacy of anti-CVB1 sera in BALB/c infection model (A–C) Seven-week-old BALB/c mice (n = 6 per group) were intravenously inoculated with 1 × 107 TCID50/mouse of rCVB1-XM0108. At 2 h post-infection, 200 μL of serially diluted anti-CVB1 sera or PBS were intraperitoneally administered. Mice were monitored for 21 days to assess (A) body weight (mean ± SEM), (B) clinical scores (mean ± SEM), and (C) survival rates. Statistical significance between dose groups was annotated on the graphs. Clinical scores (B) were analyzed using a mixed-effects model with the Šídák multiple-comparisons test. Survival curves (C) were compared using the log rank (Mantel-Cox) test. ∗∗, p < 0.01; ∗∗∗∗, p < 0.0001. Experiments were independently repeated three times, and representative results are shown. To further evaluate the protective efficacy of anti-CVB1 sera (1:10), mice (n = 3 per group per time point) were euthanized and serum and multiple organs (heart, liver, spleen, lung, kidney, brain, pancreas, and hindlimb muscles) were collected for further analysis. As shown in Figure 8A, pancreatic tissues from antiserum-treated mice appeared normal, whereas PBS-treated mice exhibited pancreatic inflammatory foci (black triangles). Histopathological analysis (Figures 8B and 8C) revealed no pathological changes or VP1 expression in the livers, pancreases, and limb muscles of antiserum-treated mice. In contrast, PBS-treated mice displayed severe pancreatitis, hepatitis, and rhabdomyolysis in hindlimb muscles. Quantitative viral load analysis (Figure 8D) showed lower viral loads in all organs of antiserum-treated mice from days 1 to 6 post-challenge, particularly in serum. Together, these data indicate that anti-CVB1 sera suppress viremia and subsequent organ dissemination.Figure 8Antiserum therapy attenuates rCVB1-XM0108-induced tissue damage and viral disseminationSeven-week-old BALB/c mice were intravenously injected with 1 × 107 TCID50 of rCVB1-XM0108. At 2 h post-infection, 200 μL of 1:10-diluted antiserum or PBS control was administered intraperitoneally.(A) Gross pancreatic morphology at 4 dpi: antiserum-treated mice show intact architecture, while PBS controls exhibit inflammatory foci (triangles).(B and C) H&E and immunohistochemical analysis of multiple organs (heart, liver, spleen, lung, kidney, brain, pancreas, and limb muscle) at 4 dpi: (B) antiserum-treated group, (C) PBS-treated group. Scale bars: 50 μm.(D) Viral RNA loads in tissues and serum from 1–6 dpi (mean ± SEM, n = 3 per group/time point). At each time point, viral RNA loads between the antiserum-treated and PBS control groups were compared using an unpaired two-tailed Student t test. n.s., not significant; ∗, p < 0.05; ∗∗, p < 0.01. Experiments were independently repeated three times, and representative results are shown. Antiserum therapy attenuates rCVB1-XM0108-induced tissue damage and viral dissemination Seven-week-old BALB/c mice were intravenously injected with 1 × 107 TCID50 of rCVB1-XM0108. At 2 h post-infection, 200 μL of 1:10-diluted antiserum or PBS control was administered intraperitoneally. (A) Gross pancreatic morphology at 4 dpi: antiserum-treated mice show intact architecture, while PBS controls exhibit inflammatory foci (triangles). (B and C) H&E and immunohistochemical analysis of multiple organs (heart, liver, spleen, lung, kidney, brain, pancreas, and limb muscle) at 4 dpi: (B) antiserum-treated group, (C) PBS-treated group. Scale bars: 50 μm. (D) Viral RNA loads in tissues and serum from 1–6 dpi (mean ± SEM, n = 3 per group/time point). At each time point, viral RNA loads between the antiserum-treated and PBS control groups were compared using an unpaired two-tailed Student t test. n.s., not significant; ∗, p < 0.05; ∗∗, p < 0.01. Experiments were independently repeated three times, and representative results are shown. Discussion CVB1 has been implicated in a wide range of human diseases, from mild febrile illnesses to life-threatening complications such as myocarditis and neonatal sepsis.3,4,5,6,7 Epidemiological studies have documented its circulation in HFMD outbreaks across diverse regions, including the United States,7 Canada,21 South Korea,22 and China.2,23,24 Despite its global prevalence, comprehensive virological and genomic characterization of clinical CVB1 isolates remains limited, and reverse genetics tools for this virus are poorly documented. In this study, a full-length infectious cDNA clone of the CVB1 clinical isolate XM0108 was successfully constructed. Using reverse genetics, we rescued the recombinant virus rCVB1-XM0108 and characterized its replication kinetics and pathogenicity in vitro and in vivo. Given the strong tropism and virulence of CVB1-XM0108 in the pancreas, liver, and skeletal muscle of BALB/c mice, we established a lethal adult mouse model of CVB1 infection. Animal infection models for CVB1 were primarily established between the 1970s and 1990s,13,25,26,27,28 indicating an urgent need for updated research. In this study, 7-week-old BALB/c mice were intravenously inoculated with 1 × 107 TCID50 of rCVB1-XM0108 per mouse. Pathological examination revealed that the virus induced acute pancreatitis, hepatitis, and myositis, ultimately leading to mouse death (Figure 2). Clinically, fatal cases of CVB1 infection are characterized by multi-organ involvement and systemic inflammatory responses,7 which were recapitulated by rCVB1-XM0108 in adult BALB/c mice (Figure 3). Conversely, early animal models of CVB1 infection were mainly characterized by single-tissue damage. For example, the Tucson strain induced myositis,27 while other CVB1 isolates caused hepatitis and/or pancreatitis in mice.26,29 While strain-specific genomic variations could contribute to these differences, this discrepancy highlights the need for comparative studies of diverse CVB1 isolates. Cases of pancreatitis caused by CVB1, CVB3, CVB4, and CVB5 within the CVB family have been reported,7,30,31 and pancreatic infection by CVB is generally considered one potential trigger for T1D.8,9,10,11 Caggana et al. demonstrated that the severity of CVB-induced pancreatitis correlates with viral genotypes.32 In our infection model, CVB1-XM0108 exhibited robust pancreatic tropism (Figure 4). Notably, in contrast to traditional hypotheses, previous studies using in situ hybridization33 and IHC34,35,36,37 (on other CVB1 strains) alongside our immunofluorescence analysis (Figure 4) have shown that rCVB1-XM0108 preferentially infects exocrine gland structures rather than islets. Intriguingly, immunohistochemical analysis of pancreatic tissues from human T1D autopsies has detected CVB protein expression in islets,38,39,40,41 which we speculate may arise from species-specific differences between mice and humans. Specifically, the expression pattern of Coxsackievirus and adenovirus receptor in mouse pancreas differs from that in humans,42,43,44,45 and pancreatic immune microenvironments also vary between species.18,46 In addition, human samples are typically obtained from chronic T1D patients, whereas mouse samples in laboratory settings are collected during acute infection; this sampling bias may underlie species-specific viral tropism differences. Currently, there are no specific antiviral drugs or vaccines approved for CVB1 infection. Passive immunotherapy has emerged as a promising strategy for rapid neutralization of enteroviruses, especially for immunocompromised patients at high risk of severe and fatal complications. Among established passive immunotherapies, human intravenous immunoglobulin (IVIG) has been clinically evaluated for the treatment of enteroviral infections.47,48,49,50 While IVIG is theoretically likely to exert a protective effect against CVB1 infection, its limited availability, inherent batch-to-batch variability in neutralizing antibody titer, and high cost make it difficult to obtain sufficient quantities for standardized preclinical evaluation in animal models. In parallel, a vaccine designed to prevent CVB1-associated T1D is currently in clinical trials,51 with preclinical data demonstrating its efficacy in protecting non-obese diabetic mice from CVB1-triggered T1D onset.52 In this study, an antiserum against CVB1-XM0108 was generated. Administration of 10-fold diluted antiserum 2 hpi protected BALB/c mice from lethal challenge of rCVB1-XM0108 and significantly alleviated virus-induced acute pancreatitis (Figures 7 and 8). These results confirm that passive immunization with CVB1-specific antiserum can effectively combat CVB1 infection in vivo. Further studies should focus on optimizing the administration window of the antiserum and assessing its therapeutic efficacy in more severe infection models. Collectively, our work enhances the understanding of passive immunotherapy against CVB1 and provides insights for developing clinical treatment strategies against CVB1 infection. In summary, this study establishes a lethal infection model in adult BALB/c mice, where rCVB1-XM0108 induces severe acute pancreatitis, hepatitis, and myositis. By recapitulating key pathological features of human CVB1 infections, this model addresses a long-standing need for immunocompetent animal systems in CVB1 research. The reverse-genetics system, together with this mouse model, provides a robust platform for interrogating strain-specific variation, virus-host interactions, and mechanisms of pathogenesis, as well as for evaluating therapeutic strategies. Future studies will leverage this system to identify the viral genetic determinants and host pathways that drive CVB1-XM0108’s enhanced virulence and multi-organ tropism, including comparative analyses across diverse clinical CVB1 isolates. Limitations of the study This study established a lethal adult BALB/c mouse infection model of CVB1 exhibiting acute pancreatitis, hepatitis, and myositis. However, the detailed mechanisms underlying multi-organ involvement by the CVB1-XM0108 strain were not explored. In addition, only female BALB/c mice were used in this study; therefore, potential sex-dependent differences in CVB1 infection and disease outcomes were not evaluated, which may limit the generalizability of the findings to male mice. Different circulating strains within the same enterovirus serotype may exhibit distinct clinical manifestations and/or tissue tropism, likely due to their high environmental adaptability and genomic variability. Furthermore, the genomic determinants differentiating CVB1-XM0108 from isolates with differing pathologies were not investigated; future studies should include comparative analyses across diverse strains. Finally, whether antiserum derived from CVB1-XM0108 confers cross-protection against other epidemic CVB1 strains remains to be determined, which is essential for evaluating the model’s broader applicability. Resource availability Lead contact Requests for further information and resources should be directed to and will be fulfilled by the lead contact, Tong Cheng (tcheng@xmu.edu.cn, Post addresses: State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences, School of Public Health, Xiamen University, Xiamen 361102, Fujian, China). Materials availability The viruses and materials used in this study can be obtained from the lead contact after the permission of original distributors. Data and code availability •The complete genome sequence of CVB1-XM0108 has been deposited in GenBank under accession number MG780414.•All other data reported in this paper will be shared by the lead contact upon reasonable request.•This paper does not report original code.•Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request. •The complete genome sequence of CVB1-XM0108 has been deposited in GenBank under accession number MG780414. The complete genome sequence of CVB1-XM0108 has been deposited in GenBank under accession number MG780414. •All other data reported in this paper will be shared by the lead contact upon reasonable request. All other data reported in this paper will be shared by the lead contact upon reasonable request. •This paper does not report original code. This paper does not report original code. •Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request. Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request. Acknowledgments This work was supported by grants from the 10.13039/501100001809National Natural Science Foundation of China (82272310, 82171833) and the Xiamen High-Quality Development Medical Innovation Project (2024GZL-CX13). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The graphical abstract was created using BioRender.com. Author contributions C.F. was responsible for the initial drafting of the manuscript, data analysis, conceptualization, and animal experiments. K.Y. performed data collection for most animal experiments and data analysis. J.X. was responsible for the histology and immunohistochemistry assays. W.F. performed the sequence analysis. N.L. and C.Y. contributed to the inflammatory response assays. W.S., S.X., J.Z., and A.L. were responsible for the plasmid preparation and in vitro characterization of viruses. D.P. prepared the CVB1 isolate. T.C., W.W., L.Z., and N.X. conceived the study and were involved in manuscript revision and refinement. Declaration of interests The authors declare no competing interests. STAR★Methods Key resources table REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesMouse monoclonal anti-VP1 (VP1-9-4)This paperN/AAnti-dsRNA Monoclonal Antibody J2 (IgG2a)SCICONSCat# Ab01299-2.3; RRID:AB_2923396Insulin (C27C9) Rabbit mAbCell Signaling Technology (CST)Cat# 3014; RRID:AB_2126503Recombinant Anti-Glucagon antibody (Rabbit mAb)Servicebio, WuhanGB153496-100Bacterial and virus strainsCVB1-XM0108This paperN/AChemicals, peptides, and recombinant proteinsDMEMMerck Sigma-AldrichD6429Fetal bovine serumThermo Fisher Scientific & GIBCOA5669701Penicillin-streptomycinThermo Fisher Scientific15140-1224′,6-diamidino-2-phenylindole dihydrochloride (DAPI)Thermo Fisher ScientificD1306MEGAscript T7 Transcription KitThermo Fisher ScientificAM1334TransIT-mRNA Transfection KitMirusMIR 2250BamHI-HFNew England Biolabs (NEB)R3136SSalI-HFNew England Biolabs (NEB)R3138SCell Counting Kit-8 (CCK-8)MedChemExpress (MCE)HY-K0301Proteome Profiler Mouse Cytokine Array Kit, Panel AR&D SystemsARY006Mouse IL-6(Interleukin 6) ELISA KitElabscienceE-EL-M0044Mouse IL-10(Interleukin 10) ELISA KitElabscienceE-EL-M0046Mouse TNF-α (Tumor Necrosis Factor Alpha) ELISA KitElabscienceE-EL-M3063Mouse IFN-γ (Interferon Gamma) ELISA KitElabscienceE-EL-M0048Freund’s Adjuvant, CompleteMerck Sigma-AldrichF5881Freund’s Adjuvant, IncompleteMerck Sigma-AldrichF5506Reverse Transcriptase M-MLV (RNase H-)TaKaRa2641BGenMagSpin Viral DNA/RNA KitGenMag Bio, Beijing, ChinaNA007-4-newGenMagScript One-Step RT-PCR KitGenMag Bio, Beijing, ChinaEZ001-2Anti-CVB1 serumThis paperN/AExperimental models: Cell linesHeLaATCCCRM-CCL-2Experimental models: Organisms/strainsMouse: BALB/cAnNShjhShanghaiJihui Laboratory Animal Care Co.Ltd.1003OligonucleotidesSee in Table S1Nanjing Genscript Bio, Inc.N/ARecombinant DNApSVA-CVB1-XM0108This paperN/ASoftware and algorithmsGraphPad PrismGraphPad Prism version 10.00https://www.graphpad.com/featuresBioRenderBioRender.comhttps://www.biorender.comCaseViewer3DHISTECHhttps://www.3dhistech.comMEGAMEGA11.0https://www.megasoftware.net/Deposited dataCVB1-XM0108 complete genome sequenceThis paperGenBank: MG780414.1 REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesMouse monoclonal anti-VP1 (VP1-9-4)This paperN/AAnti-dsRNA Monoclonal Antibody J2 (IgG2a)SCICONSCat# Ab01299-2.3; RRID:AB_2923396Insulin (C27C9) Rabbit mAbCell Signaling Technology (CST)Cat# 3014; RRID:AB_2126503Recombinant Anti-Glucagon antibody (Rabbit mAb)Servicebio, WuhanGB153496-100Bacterial and virus strainsCVB1-XM0108This paperN/AChemicals, peptides, and recombinant proteinsDMEMMerck Sigma-AldrichD6429Fetal bovine serumThermo Fisher Scientific & GIBCOA5669701Penicillin-streptomycinThermo Fisher Scientific15140-1224′,6-diamidino-2-phenylindole dihydrochloride (DAPI)Thermo Fisher ScientificD1306MEGAscript T7 Transcription KitThermo Fisher ScientificAM1334TransIT-mRNA Transfection KitMirusMIR 2250BamHI-HFNew England Biolabs (NEB)R3136SSalI-HFNew England Biolabs (NEB)R3138SCell Counting Kit-8 (CCK-8)MedChemExpress (MCE)HY-K0301Proteome Profiler Mouse Cytokine Array Kit, Panel AR&D SystemsARY006Mouse IL-6(Interleukin 6) ELISA KitElabscienceE-EL-M0044Mouse IL-10(Interleukin 10) ELISA KitElabscienceE-EL-M0046Mouse TNF-α (Tumor Necrosis Factor Alpha) ELISA KitElabscienceE-EL-M3063Mouse IFN-γ (Interferon Gamma) ELISA KitElabscienceE-EL-M0048Freund’s Adjuvant, CompleteMerck Sigma-AldrichF5881Freund’s Adjuvant, IncompleteMerck Sigma-AldrichF5506Reverse Transcriptase M-MLV (RNase H-)TaKaRa2641BGenMagSpin Viral DNA/RNA KitGenMag Bio, Beijing, ChinaNA007-4-newGenMagScript One-Step RT-PCR KitGenMag Bio, Beijing, ChinaEZ001-2Anti-CVB1 serumThis paperN/AExperimental models: Cell linesHeLaATCCCRM-CCL-2Experimental models: Organisms/strainsMouse: BALB/cAnNShjhShanghaiJihui Laboratory Animal Care Co.Ltd.1003OligonucleotidesSee in Table S1Nanjing Genscript Bio, Inc.N/ARecombinant DNApSVA-CVB1-XM0108This paperN/ASoftware and algorithmsGraphPad PrismGraphPad Prism version 10.00https://www.graphpad.com/featuresBioRenderBioRender.comhttps://www.biorender.comCaseViewer3DHISTECHhttps://www.3dhistech.comMEGAMEGA11.0https://www.megasoftware.net/Deposited dataCVB1-XM0108 complete genome sequenceThis paperGenBank: MG780414.1 Experimental model and study participant details All animal experiments were performed using 7-week-old female wild-type (WT) specific pathogen-free (SPF) BALB/c mice purchased from Shanghai Jihui Laboratory Animal Care Co., Ltd. (Shanghai, China). Mice were housed under SPF conditions at 22°C with a 12-h light/dark cycle and ad libitum access to food and water. All animal procedures were approved by the Institutional Animal Care and Use Committee and Laboratory Animal Management Ethics Committee of Xiamen University (Permission No. XMULAC20200231). CVB1-XM0108 is a Coxsackievirus B1 strain whose complete genome sequence has been deposited in GenBank under accession number MG780414. The recombinant virus rCVB1-XM0108 was rescued from the infectious cDNA clone pSVA-CVB1-XM0108, propagated in HeLa cells, purified, and stored at −80°C until use. HeLa cells, a human cervical carcinoma cell line of female origin, were obtained from the American Type Culture Collection (ATCC). Cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM; D6429, Merck Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS; A5669701, Thermo Fisher Scientific/Gibco), 100 U/mL penicillin, and 100 μg/mL streptomycin (15140–122, Thermo Fisher Scientific). Method details Ethics statement Animal experiments were conducted in accordance with protocols approved by the Institutional Animal Care and Use Committee and Laboratory Animal Management Ethics Committee of Xiamen University (Permission NO. XMULAC20200231). Determination of the full-length viral genome sequence The CVB1-XM0108 strain was isolated from the cerebrospinal fluid of a child with aseptic meningitis in China in 2011. First-strand cDNA was synthesized from the extracted total RNA using oligo (dT) primers and M-MLV reverse transcriptase (2641, TaKaRa) following the manufacturer’s protocols. The resultant first-strand cDNA was used as a template for subsequent PCR. Parts of the viral genome were amplified and sequenced. BLAST analysis of the amplified sequences against the NCBI database confirmed homology with the CVB1 genome. Based on the obtained partial sequences and the published CVB1SD2011CHN strain (GenBank: JX976769.1), primers were designed to amplify the complete CVB1 genome. The full-length genome was then amplified using overlapping segmented primers and Sanger sequenced. Primers used for PCR amplification and sequencing are listed in Table S1. The complete viral genome sequence of CVB1-XM0108 has been deposited in GenBank (GenBank: MG780414.1). Phylogenetic analysis Phylogenetic analysis of complete CVB1 viral genomes was performed using the MEGA program (version 11.0)53 with the Neighbor-Joining method and 1,000 bootstrap replications. Construction of infectious clone and virus rescue The full genome sequence of CVB1-XM0108 was cloned into the pSVA vector using a method described previously.54 Briefly, genomic RNA was synthesized via in vitro transcription using the MEGAscript T7 Transcription Kit (AM1334, Thermo Fisher Scientific). RNA integrity was verified by 1% agarose gel electrophoresis, which showed distinct bands. Following purification, 2 μg of viral RNA was transfected into HeLa cells using the TransIT-mRNA Transfection Kit (MIR 2250, Mirus) according to the manufacturer’s protocol. HeLa cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM; D6429, Merck Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS; A5669701, Thermo Fisher Scientific/Gibco), 100 U/mL penicillin, and 100 μg/mL streptomycin (15140–122, Thermo Fisher Scientific). Upon observing extensive cytopathic effects (CPE), virus-containing supernatants were collected and clarified by centrifugation at 6,000×g for 30 min at 4 °C to remove cellular debris. Viral particles were precipitated overnight at 4 °C using 6% (w/v) polyethylene glycol (PEG) 6000. The precipitate was resuspended in PBS and layered onto a 15–45% (w/v) sucrose density gradient, followed by ultracentrifugation at 30,000 rpm for 4.5 h (h) at 4 °C using an SW41 rotor. The purified virus was dialyzed against PBS at 4 °C and stored at −80 °C. Viral titers were determined in HeLa cells by calculating the 50% tissue culture infectious dose (TCID50) using the Reed–Muench method. Transmission electron microscopy Purified viral particles were fixed with a 1% (v/v) glutaraldehyde solution and incubated on a parafilm surface for 10 min. A carbon-coated, formvar-covered 200-mesh grid (Plano GmbH) was subsequently placed on each droplet for 5 min to allow viral particle adsorption, and then excess liquid was gently blotted with filter paper. The grids were negatively stained by immersion in a droplet of 2% phosphotungstic acid (pH 6.4) for 30 s, followed by removal of residue stain with filter paper. After airdrying, the grids were examined using a Tecnai G2 Spirit transmission electron microscope (FEI) for image capture. Determination of one-step viral growth curves To characterize the replication dynamics of the CVB1-XM0108 strain, one-step growth curves were determined. Briefly, confluent HeLa cells in 24-well plates were inoculated with CVB1-XM0108 or the rescued virus derived from the infectious clone pSVA-CVB1-XM0108 (rCVB1-XM0108) at a multiplicity of infection (MOI) of 0.1. After 1 h of absorption at 37 °C, unbound virus was removed by three washes with PBS, and cells were overlaid with fresh DMEM. The infected cells were incubated at 37 °C for 2, 4, 6, 8, 16, 24, 48 and 72 h post-inoculation. At each time point, cells and supernatants were collected, subjected to three freeze-thaw cycles to release intracellular virus, and viral titers were determined by TCID50 assay in triplicate. Viral titers (Log10TCID50/mL) were plotted against time post-inoculation to generate one-step growth curves, and data were analyzed using GraphPad Prism software (Version 10.0). Immunofluorescence assay For double immunofluorescence staining, the CVB1 structural protein VP1 was detected using an anti-VP1 mouse monoclonal antibody (mAb; VP1-9-4) produced in our lab. The primary anti-VP1 mAb was probed with a fluorescein isothiocyanate (FITC)-conjugated goat-anti-mouse secondary antibody. Viral replicative intermediates (dsRNA) were detected using an anti-dsRNA mAb J2 (SCICONS),55 followed by incubation with a tetramethyl rhodamine isothiocyanate (TRITC)-conjugated goat-anti-mouse secondary antibody. Cell nuclei were counterstained with 4′,6-diamidino-2-phenylindole dihydrochloride (DAPI; Thermo Fisher Scientific). Fluorescence images were acquired using a Zeiss LSM 780 fluorescent confocal microscope (63× oil immersion objective; Zeiss, Germany). Cell viability assay HeLa cells were seeded into 96-well plates at a density of 1 × 104 cells per well and infected with CVB1-XM0108 and rCVB1-XM0108 at MOIs ranging from 0.00001 to 10. At each time point, cell viability was determined as the percentage of viable cells using the Cell Counting Kit-8 (CCK-8) assay (HY-K0301, MCE) according to the manufacturer’s instructions. Animal experiments Seven-week-old female BALB/c mice (n = 6 per group) were randomly assigned to different groups. For the infected group, mice were intravenously injected with 200 μL of rCVB1-XM0108 at doses ranging from 1 × 105 to 1 × 108 TCID50 per mouse, which were prepared by 10-fold serial dilutions in PBS from a viral stock with a titer of 7.5 × 109 TCID50/mL. The control group received a single intravenous injection of 200 μL PBS. Body weight, survival rates and clinical scores of the mice were recorded daily for 21 days. Clinical symptoms were monitored and scored daily for 21 days post-infection using a validated 5-point scoring scale adapted from established murine enterovirus infection models14,56: 0, healthy; 1, lethargy and inactivity; 2, wasting; 3, limb weakness; 4, hindlimb paralysis; 5, moribund or dead. Mice that reached the pre-defined humane endpoint (moribund state) and were euthanized, or mice that died naturally, were assigned a terminal score of 5 on the day of euthanasia or death, with no further clinical scoring performed for these animals at subsequent time points. Serum sample collection and preparation Blood samples were collected from mice via retro-orbital bleeding at indicated time points. Samples were allowed to clot at room temperature for 30 min and then centrifuged at 4,000 × g for 15 min at 4 °C to separate serum. The serum was carefully collected, aliquoted to avoid repeated freeze-thaw cycles, and stored at −80 °C until further use. Quantitative real-time PCR RNA was extracted from serum samples and tissue homogenates using a GenMagSpin Viral DNA/RNA Kit (GenMag Bio, Beijing, China). Real-time PCR analysis was performed with gene-specific primers using a One-Step RT-PCR Kit (GenMag Bio, Beijing, China) and Roche 96 system according to the manufacturer’s protocol. The PCR reaction conditions were 15 min at 42 °C and 15 min at 95 °C, followed by 40 cycles of 95 °C for 15 s and 55 °C for 55 s. The plasmid, pMD18-CVB1, was constructed by inserting the amplified fragments from the primers into a pMDTM 18-T Vector (TaKaRa) and was used as the standard sample. The copies of CVB1 genome were quantified using a standard curve generated from serially diluted standard plasmid. Primers used for RT-qPCR are listed in Table S1. Histology and immunohistochemistry assay 7-week-old BALB/c mice were intravenously inoculated with rCVB1-XM0108 strain at a dose of 1 × 107 TCID50 per mouse (n = 3 per group). Moribund mice were humanely euthanized via carbon dioxide anesthesia. Tissues, including the heart, spleen, lung, kidney, brain, pancreas, and limb muscle were surgically excised and fixed in formalin for histological analysis. Formalin-fixed tissues were paraffin-embedded, serially sectioned (5 μm thickness), and processed for haematoxylin-eosin (H&E) staining and immunohistochemistry (IHC) staining as previously described.57 For IHC, the VP1-9-4 mAb was used at a 1:1,000 dilution (working concentration: 1 μg/mL) to detect the CVB1 VP1 protein. An insulin rabbit mAb (3014, Cell Signaling Technology) was used at a 1:500 dilution to visualize pancreatic β cells. Multiplex immunofluorescence assays were performed with technical support from Servicebio (Wuhan, China). Tissue sections underwent heat-induced antigen retrieval in citrate buffer (pH 6.0) followed by blocking with 3% bovine serum albumin (BSA). Primary antibodies, including mouse anti-VP1 (VP1-9-4, 1:1,000), rabbit anti-insulin (3014, Cell Signaling Technology, 1:500), and rabbit anti-glucagon (Servicebio, 1:500) were applied overnight at 4 °C. After PBS washes, different fluorochrome-conjugated secondary antibodies (Servicebio) were incubated for 1 h at room temperature. Nuclei were counterstained with DAPI (Thermo Fisher Scientific). Whole-slide imaging was performed using a 3DHISTECH Panoramic MIDI Digital Slide Scanner with a 20× objective. Blood biochemical analysis Serum samples were collected daily (days 0–7 post-infection). Concentrations of serum alanine transaminase (ALT), aspartate aminotransferase (AST), α-amylase (α-AMY) were measured using commercial assay kits (Mindray) according to the manufacturer’s protocols. Cytokines and chemokines detection Forty mouse cytokines, chemokines and acute-phase proteins in mouse serum were simultaneously determined using a membrane-based antibody array kit (ARY006, R&D Systems) at 4 dpi according to the manufacturer’s instructions. In addition, the concentrations of TNF-α, IFN-γ, IL-6 and IL-10 in the serum were determined with individual mouse ELISA detection kits (Elabscience) following the manufacturer’s instructions. Optical density (OD) values at 450 and 630 nm were measured using a microplate reader and the cytokine concentrations were calculated from standard curves using linear regression. The theoretical limits of detection were 18.75 pg/mL (TNF-α), 9.38 pg/mL (IFN-γ), 18.75 pg/mL (IL-6) and 9.38 pg/mL (IL-10) respectively. Protection efficacy of ANTI-CVB1 SERA in BALB/C mice For the preparation of anti-CVB1 sera, 7-week-old female BALB/c mice were subcutaneously immunized with 0.01% formaldehyde-inactivated supernatant of the rCVB1-XM0108 strain, which was derived from a viral stock with a titer of 7.5 × 109 TCID50/mL and administered at a dose of 1 × 107 TCID50/mouse. Mice received a primary immunization with antigen emulsified in complete Freund’s adjuvant (F5881, Merck Sigma-Aldrich), followed by two booster immunizations at 2-week intervals using the same antigen formulated in incomplete Freund’s adjuvant (F5506, Merck Sigma-Aldrich). Sera were collected 2 weeks after the final booster, inactivated by 30-min incubation at 56 °C, and stored at −20 °C for subsequent in vitro neutralization and in vivo protection assays. For the in vitro neutralization assay, confluent HeLa cell monolayers were dissociated, resuspended in DMEM, and seeded into 96-well plates at a density of 4 × 103 cells per well. Antisera were serially diluted 2-fold in DMEM (1:16 to 1:4096), with each dilution mixed equally with the infectious rCVB1-XM0108 strain (100 TCID50) and incubated at 37 °C for 1 h. The mixtures were added to pre-seeded HeLa cells and cultured for 5–7 days. After incubation, cytopathic effects (CPE) were monitored microscopically. Neutralizing titers were determined as the highest antiserum dilution that completely prevented CPE in over 50% of wells and reported as the geometric mean of triplicate measurements. To evaluate the protection efficacy of anti-CVB1 sera in BALB/c mice, 7-week-old BALB/c mice (n = 6 per group) were intravenously infected with the rCVB1-XM0108 strain at a dose of 1 × 107 TCID50 in 200 μL PBS. To evaluate the protective efficacy of antisera, a single intraperitoneal injection of serially diluted antisera (1:10 to 1:10,000, 10-fold increments) in 200 μL PBS was administered 2 h post-infection (hpi). Control mice received an equivalent volume of PBS via the same intraperitoneal route. Body weight, clinical symptoms, and survival rates were monitored daily during a 21-day observation period. To further evaluate the protective efficacy of anti-CVB1 sera (1:10), mice were euthanized daily from 1 to 6 dpi, and serum as well as multiple organs, including the heart, liver, spleen, lung, kidney, brain, pancreas, and hindlimb muscle, were collected for RT-qPCR analysis (n = 3 per group per time point). In addition, at 4 dpi, mice (n = 3 per group) were euthanized and the harvested organs were subjected to histopathological and immunohistochemical analyses. Quantification and statistical analysis All statistical analyses were performed using GraphPad Prism version 10 (GraphPad Software, San Diego, CA, USA). Data are presented as mean ± SEM unless otherwise indicated. For animal experiments, n represents the number of individual mice, with each mouse considered an independent biological unit. Each experiment was independently repeated three times, and the n values reported in the figures and figure legends refer to the individual mice included in the representative experiment shown rather than pooled animals from the three independent experiments. Comparisons between two groups at individual time points were performed using unpaired two-tailed Student’s t-tests. Longitudinal or multigroup data were analyzed using two-way ANOVA or mixed-effects models, as indicated in the corresponding figure legends, with Šídák’s multiple-comparisons test where applicable. Survival curves were compared using the log rank (Mantel–Cox) test. A p value <0.05 was considered statistically significant. Statistical significance is indicated as n.s., not significant; ∗, p < 0.05; ∗∗, p < 0.01; ∗∗∗, p < 0.001; and ∗∗∗∗, p < 0.0001.